(Q39095950)

9 September 2017

Knockdown of cyclophilin A reverses paclitaxel resistance in human endometrial cancer cells via suppression of MAPK kinase pathways (English)

1 reference

9 September 2017

1 reference

1 reference

Zhengyu Li

1

1 reference

PubMed ID

24036847

9 September 2017

Wenjiao Min

series ordinal

2

1 reference

PubMed ID

24036847

9 September 2017

Jinhai Gou

series ordinal

3

1 reference

9 September 2017

14 September 2013

1 reference

Cancer Chemotherapy and Pharmacology

9 September 2017

1 reference

9 September 2017

72

1 reference

9 September 2017

5

1 reference

9 September 2017

1001-1011

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-013-2285-8

9 September 2017

0 references

cites work

Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

Medical therapy of endometrial cancer: current status and promising novel treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

Proteomics identification of cyclophilin a as a potential prognostic factor and therapeutic target in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

Overexpressed cyclophilin A in cancer cells renders resistance to hypoxia- and cisplatin-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

Oligo-microarray analysis reveals the role of cyclophilin A in drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

Molecular basis for class V beta-tubulin effects on microtubule assembly and paclitaxel resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

Human mutations that confer paclitaxel resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

Understanding the basis of drug resistance of the mutants of αβ-tubulin dimer via molecular dynamics simulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

βII-tubulin and βIII-tubulin mediate sensitivity to peloruside A and laulimalide, but not paclitaxel or vinblastine, in human ovarian carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

Cancer cells acquire mitotic drug resistance properties through beta I-tubulin mutations and alterations in the expression of beta-tubulin isotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

Mutational analysis of the beta-tubulin gene in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

Parvulin 17 promotes microtubule assembly by its peptidyl-prolyl cis/trans isomerase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

Role of cyclophilin a during oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

Proteomic analysis of the resistance to aplidin in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

Multidrug resistance-associated proteins and implications in drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

Targeting survivin in cancer: patent review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

PPIase independent chaperone-like function of recombinant human Cyclophilin A during arginine kinase refolding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

Active site residues of cyclophilin A are crucial for its signaling activity via CD147

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

Evidence that intracellular cyclophilin A and cyclophilin A/CD147 receptor-mediated ERK1/2 signalling can protect neurons against in vitro oxidative and ischemic injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

Cyclophilin A is overexpressed in human pancreatic cancer cells and stimulates cell proliferation through CD147.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

Cyclophilin A is upregulated in small cell lung cancer and activates ERK1/2 signal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

Cyclophilin A enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

Downregulation of cyclophilin A by siRNA diminishes non-small cell lung cancer cell growth and metastasis via the regulation of matrix metallopeptidase 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2285-8

10.1007/S00280-013-2285-8

21 January 2018

Identifiers

DOI

1 reference

9 September 2017

1 reference

PubMed ID

24036847